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Summary The purpose of the study was to ascertain whether the prognostic significance of staging in
multiple myeloma (MM) is influenced by the aggressiveness of effective induction treatment and/or by
continuing or discontinuing maintenance chemotherapy. Patients with untreated stage I MM (defined accord-
ing to Durie and Salmon) were randomised between being followed without cytostatics until the disease
progressed and receiving six courses ofmelphalan and prednisone (MP-P) just after diagnosis; stage II patients
were uniformly treated with MPH-P and stage III patients were randomised between MPH-P and four courses
of combination chemotherapy with Peptichemio, vincristine and prednisone (PTC-VCR-P). Within each stage,
responsive patients were randomised between receiving additional therapy only until maximal tumour reduc-
tion was reached (plateau phase) and continuing induction therapy indefinitely until relapse. With resistant,
progressive or relapsing disease, patients originally treated with MPH-P for induction received combination
chemotherapy and vice versa. The overall first response rate was 43.8% (42.2% in 206 stage I, II and III
patients treated with MPH-P and 48.0% in 75 stage III patients treated with combination chemotherapy,
P = NS). Combination chemotherapy was more myelotoxic than MPH-P and, in particular, caused more
non-haematological side-effects. Both the less and the more aggressive induction policies gave the same disease
control. Progression of disease was statistically similar in stage I patients who were initially left untreated and
in those who received MPH-P just after diagnosis; median duration of first response was similar in stage III
patients receiving MPH-P and in those on combination chemotherapy. In all stages, discontinuing or
continuing maintenance did not alter the median duration of first response. The overall second response rate
was 28.5% (34.0% to MPH-P and 25.3% to combination chemotherapy, P= NS). Median survival was
greater than 78 months in stage I, was 46.3 months in stage II and was 24.3 months in stage III patients, still
independent of both induction and post-induction policies. In MM, the significance of staging for survival is
independent of both the aggressiveness of induction policy and of continuing or discontinuing maintenance
chemotherapy after the maximal tumour reduction has been achieved. Both MPH-P and the association of
PTC, VCR and P are effective in inducing first response and also second response in patients failing on the
alternative regimen, but PTC-VCR-P causes more side-effects. Thus, the overwhelming majority of patients
with MM can safely be given MPH-P as first therapy, and this treatment may be delayed in early
disease.
Attempts to improve survival of the general population of
patients with multiple myeloma (MM) have been focused
mainly on chemotherapies more aggressive than the standard
melphalan-prednisone (MPH-P) regimen, irrespective of the
extent of the disease. Little has been done to evaluate, in
prospective studies, the survival value of tailoring therapy
according to the stage of the disease, as is done with several
other tumours in spite of there being no doubt that early
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disease, i.e. stage I MM (Durie & Salmon, 1975) (which is
sometimes difficult to distinguish from monoclonal gammo-
pathies of undetermined significance, MGUS), is a far less
dramatic disease than advanced (stage III) disease and that
the two conditions could require different treatment
strategies.
Retrospective analyses, as well as a recent meta-analysis
(Gregory et al., 1992), suggest that early MM patients do not
benefit from aggressive induction chemotherapy (Harley et
al., 1979; Cavagnaro et al., 1980; Salmon et al., 1983; Cooper
et al., 1986; Riccardi et al., 1986; Kildahl-Andersen et al.,
1988; MacLennan et al., 1988; Hjorth et al., 1990; Boccadoro
et al., 1991), whereas advanced cases do (Harley et al., 1979;
Salmon et al., 1983; Cooper et al., 1986). The question,
however, has not been addressed in properly designed, pros-
pective investigations.
The survival value of continuing or discontinuing cyto-
static maintenance following response has been considered in
some series, yet with poorly defined results (Alexanian et al.,
1978; Cohen et al., 1979; MacLennan & Cusick, 1985; Belch
et al., 1988; Kildahl-Andersen et al., 1988) (also taking into
account the fact that long-term alkylating therapy increases
the risk of acute leukaemia) (Bergsagel et al., 1979).
This prospective, randomised study (referred to as Protocol
MM87, the results of which are reported here) was aimed at
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ascertaining whether the survival of patients with MM could
be influenced by the choice between more and less aggressive
induction chemotherapies (which differed depending on the
stage of disease) and by continuing or discontinuing cyto-
static maintenance therapy in responsive patients.
Patients with stage I and III disease were randomised
between induction policies, less and more aggressive respec-
tively, than the standard MPH-P treatment (which was
administered to all stage II patients). For stage I disease, the
less aggressive induction policy that we compared with
MPH-P was the withholding of cytostatics until progression.
For stage III patients, the more aggressive induction policy
we compared with MPH-P combination chemotherapy was
the association of Peptichemio (PTC), vincristine (VCR) and
prednisone. PTC is a cytostatic composed of sarcolysin cova-
lently bound to six peptides in order to combine alkylating
and antimetabolic effects (De Barbieri et al., 1972; Pom-
matau et al., 1977). This drug, given alone (Cavo et al., 1981;
Merlini et al., 1982; Buzaid & Durie, 1988) or combined with
VCR and P (Merlini et al., 1985; Riccardi et al., 1986),
induces response in approximately 50% of untreated (Cavo
et al., 1981; Merlini et al., 1985; Riccardi et al., 1986) and
resistant (Merlini et al., 1982; Buzaid & Durie, 1988) plasma
cell tumours, including plasma cell leukaemia (Montecucco et
al., 1986). In a randomised study, the association of PTC,
VCR and P proved to be more aggressive than MPH-P
(Riccardi et al., 1986). In fact, the percentage of responses
was greater (58 vs 41%) and responses were more rapidly
achieved (the half-time of MC reduction was 55 vs 181
days).
Responsive patients were randomised (within each stage):
some received the same cytostatic therapy until the maximum
reduction in tumour mass was reached and then discontinued
it until relapse; others continued this therapy indefinitely
until relapse, as maintenance therapy. Third- and fourth-line
therapies and supportive measures completed the protocol.
Materials and methods
The prospective multicentre, randomised Protocol MM 1987
was started in January 1987 and closed in March 1990.
During this time, 355 consecutive patients with untreated
MM were enrolled from internal medicine, haematology and
oncology units.
Diagnosis andstaging
Diagnosis of MM required the presence of at least two of the
three following features: (a) a serum and/or urine mono-
clonal component (MC); (b) a bone marrow plasma cell
(BMPC) infiltration greater than 20%, as evaluated on
trephine BM biopsy (Riccardi et al., 1990); (c) the presence
of osteolytic lesions unattributed to other causes. For diag-
nosis of non-secretory MM (i.e. for patients fulfilling criteria
b and c only), the biopsy of a lytic lesion was required.
Criteria were also established for diagnosis of solitary
osseous plasmacytoma (in the absence of criteria a or b the
solitary lytic lesion had to be biopsied; in the absence of b
only it was accepted that MC had disappeared after radiation
therapy): extramedullary plasmacytoma (biopsy was always
required) and primary plasma cell leukaemia (in the presence
of features fulfilling the diagnosis of MM, circulating plasma
cells had to be >20% of WBC or >2.0 x 1091- in absolute
number). These entities, however, do not enter this
report.
Other causes of increased marrow plasmacytosis (e.g.
rheumatoid arthritis, chronic infections, collagen disease, car-
cinoma, lymphoma or leukaemia, aplastic anaemia) and of
monoclonal gammopathy (e.g. serum sickness, tuberculosis,
neoplasms) had to be carefully excluded before a diagnosis of
MM or MGUS was made.
Staging
Upon admission, patients were staged (Durie & Salmon,
1975) after adequate hydration.
Randomisations
The protocol included two randomisations effected by a Cen-
tral Secretariat at the Clinica Medica II of the University of
Pavia.
The first randomisation was between less and more aggres-
sive induction cytostatic policies for stage I and stage III
patients. This randomisation was effected (from a computer-
generated list) just after the name, the affiliation and the
stage of the patient were communicated by phone or fax.
The second randomisation was between discontinuing or
continuing maintenance. It was effected on completion of
induction therapy in partial and complete responders, and
balanced on stage and type of response (partial or com-
plete).
Induction treatment
Stage I MM patients were randomised between a non-aggres-
sive policy (no treatment until progression) and treatment
just after diagnosis with MPH (0.21 mg kg-' day-' p.o., days
1-4) and P (0.50 mg kg-' day-' p.o., days 1-10), given at 6
week intervals for six courses. The doses of MPH were
decreased or increased, in order to maintain a 6-8 week
interval between MPH-P courses, if cytopenia was, respec-
tively, greater or less than expected (nadir of granulocytes at
about 2.0 x 1091' and of platelets at about 80 x 109I` at 3
weeks after starting the course, with recovery between weeks
4 and 6), because of individual differences in gastrointestinal
MPH absorption.
Untreated patients were kept on follow-up without therapy
until progression occurred. Once the disease fulfilled the
criteria for stage II or III MM, they were treated according
to the higher stage reached.
Patients with stage II MM were uniformly treated with
MPH and P, according to the schedule reported above.
Patients with stage III MM were randomised between a
less aggressive treatment (i.e. MPH-P at the above-mentioned
schedule) and a more aggressive combination chemotherapy,
i.e. the association of PTC (Istituto Sieroterapico Milanese,
Milan, 0.8 mg kg-' day-' by i.v. infusion, days 1, 3 and 5),
VCR (0.025 mg kg- day-', maximal dose 2mg, days 1 and
14) and P (0.4 mg kg-' day-', days 1-7) given every 28 days
for four courses. The PTC was diluted in 250 ml of 5%
glucose solution and infusion lasted 30-45 min and was
followed by a rapid washing of the vein with 250ml of
saline. With PTC-VCR-P the nadir of granulocytes was
expected between days 9 and 15 and recovery by day 28
(Riccardi et al., 1986). If a more prolonged cytopenia ensued
in these patients, the next course was delayed.
Response evaluation
Patients were evaluated for response at the end of induction
therapy, i.e. after six courses of MPH-P or four courses of
PTC-VCR-P, according to clinical criteria slightly modified
from those adopted by the SECSG (Cohen et al., 1979).
Criteria were as follows: (a) reduction in MC; (b) decrease in
BMPC of at least 20% or return to less than 20%, as
evaluated on BM imprints before and after treatment; (c) a
2 gdl-' rise in Hb concentration in anaemic patients
(Hb<1 g dl-') sustained for more than 4 weeks; (d) return
of serum calcium and blood urea nitrogen (BUN) to normal
values; (e) elevation of serum albumin to 3 g dl-' or more in
the absence of other causes ofhypoalbuminaemia; (f) absence
of progression of skeletal lytic lesions.
Complete response (CR) was a >50% reduction in MC
and a response in more than half of the other parameters.
Partial response (PR) was a 25-50% reduction in MC and a
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response (NR) was non-fulfilment of the above criteria for
CR and PR. Progression was a >25% increase in MC
and/or an increase in BMPC of at least 20% and/or worsen-
ing of laboratory parameters (mainly haemoglobin, serum
calcium and blood urea nitrogen) and/or of skeletal lytic
lesions.
Maintenance therapy and relapse
As soon as induction therapy was completed, responsive
patients (CR and PR) were randomised, within each stage,
between receiving additional therapy in order to achieve the
maximum reduction in MC (i.e. the plateau phase), and then
stopping cytostatic treatment until relapse, or continuing
therapy indefinitely until relapse, as maintenance. Post-
induction therapy was the same as induction therapy, except
that only one dose of both PTC and VCR was administered
(on day 1) in the combination chemotherapy arm.
The plateau phase was arbitrarily defined as being when
the lowest MC did not change >25% (at scanning serum or
concentrated urine electrophoresis) for 6 months, with stable
clinical, haematological and radiological conditions.
Relapse was defined as a >50% increase in the plateau
level of MC and/or an increase in the size and/or number of
skeletal lytic lesions.
Treatment ofresistant, progressive and relapsing patients
Patients who were resistant with one regimen or who pro-
gressed or relapsed during maintenance with this regimen
were crossed to the other regimen, as a second-line therapy.
So, patients who were originally treated with MPH-P for
induction (whether stage I or II or III patients) were treated
with PTC-VCR-P combination chemotherapy, and patients
originally treated with PTC-VCR-P combination chemo-
therapy (who were stage III patients) were treated with
MPH-P. Patients who achieved response on second-line treat-
ment continued on maintenance therapy with the same drugs
until relapse.
Second-line therapy was delayed in patients who relapsed
while receiving no maintenance. On relapse, these patients
resumed the first induction treatment, and second-line
therapy was used in case of resistance and on second
relapse.
Guidelines were given for further cytostatic treatment of
patients who failed on both MPH-P and PTC-VCR-P as well
as for treatment of complications with supportive care.
Follow-up
At diagnosis a complete history was obtained and the general
performance and objective clinical status of the patient were
assessed, together with a number of routine haematological
laboratory parameters (including erythrocyte sedimentation
rate, haemoglobin level, white cell count and differential,
platelets, serum creatinine, urea nitrogen, uric acid, calcium,
protein electrophoresis, and normal immunoglobulin level, as
assessed by serum radial immunodiffusion, immunoelectro-
phoresis or immunofixation), 24 h urine examination (for
Bence Jones proteinuria, calciuria, hydroxyprolinuria), BM
biopsy and aspiration (with myelogram, for the BMPC %),
complete radiological bone survey and special evaluations
(such as plasma viscosity, serum alkaline phosphatase isoen-
zymes, serum P2-microglobulin and thymidine kinase levels,
bone marrow plasma cell labelling index, DNA flow
cytometry and standard cytogenetics of bone and/or
peripheral blood cells) (Riccardi et al., 1991).
Blood and 24 h urine laboratory tests were repeated every
2 months throughout the induction period and then every
third or fourth month. BM examination, skeletal radiographs
and special investigations were repeated at 6-month intervals
or at shorter intervals, according to clinical need.
Data collection
Just after first randomisation, a protocol entrance form had
to be completed (specifying data which validated the diag-
nosis and the stage) and a photocopy sent to the coor-
dinating centre. In doubtful cases, additional information
was obtained from the physician in charge.
Every 6 months the entrance form was updated and
cooperative group meetings were held regularly in Pavia, to
present and discuss data and problems.
Information on the occurrence and duration of response(s)
was obtained from the forms. Duration of response was
calculated from the end of successful induction therapy until
relapse, and surviving patien-ts who had no relapse during
follow-up were censored (patients who died before relapse
were considered as events). Survival was calculated from the
time of randomisation to the time of death, as obtained from
the forms or from a death certificate-based search. Nine
patients could not be traced and their last follow-up visit was
effected more than 1 year before.
Statistical evaluation
Differences in the response rate among the different groups
of patients were tested by the contingency table chi-square
test. Response duration and survival curves were obtained
using the method of Kaplan and Meier, and differences
between curves were analysed by the log-rank test.
Results
Of the 355 patients who were referred to the coordinating
centre, 341 fulfilled the diagnostic criteria for MM and
entered the protocol. Their main clinical and immuno-
chemical characteristics are summarised in Table I. For all
patients, median value for P2-microglobulin was 4.4 (range
1.2-22.0) mg I-'. It was 2.8 (range 1.2-12.9) mgI` in stage
I patients, 3.3 (range 1.3-10.4)mgl l in stage II patients
and 6.3 (range 2.0-22.0)mg1-' in stage III patients.
Causes for 14 patients were excluded were lack of sufficient
data (four patients) and a final diagnosis of solitary plas-
macytoma (four patients), of extramedullary plasmacytoma
(one patient), of plasma cell leukaemia (one patient) and of
cancer with serum MC (four patients).
At the time of this analysis (May 1993), 202 (59%)
enrolled patients (25, 61 and 73% of stage I, II and III
respectively) have died. The median follow-up of the 139
living patients is 51 months and the minimum follow-up is 39
months.
First induction therapy
Of 341 patients who entered the protocol, 301 received the
first induction therapy (40 were stage I patients who were
randomised to receive no cytostatics until progression) and
281 are evaluable for response (Table II). The causes for
which the remaining 20 patients (6.6% of those treated) were
not evaluable were refusal of cytostatic therapy (two
patients), insufficient data (nine patients) and loss to follow-
up (nine patients).
Overall, the response rate was 43.8%: 42.2% in 206 stage
I, II and III patients treated with MPH-P and 48.0% in 75
stage III patients treated with combination chemotherapy
(P= NS). Other data on response (and early deaths) by stage
and treatment are detailed in Table II. Among 38 stage III
patients with B disease (i.e. with renal insufficiency), 21 were
treated with combination chemotherapy and 14 (66.7%) res-
ponded, while 17 were treated with MPH-P and four (29.4%)
responded (P<0.01).
Among 69 patients on whom data were available for
analysis, the median time to response was shorter for 25
treated with combination chemotherapy than for 44 treated
with MPH-P (13.2 vs 21.2 weeks, P<0.05). The maximal
tumour reduction (i.e. the plateau phase following response)1206 A. RICCARDI et al.
Table I Main clinical and immunochemical characteristics of the
studied population, whose median age was 66 (range 33-87) years
(stage was according to Durie & Salmon)
No. %
341
168
173
Patients
Males
Females
Serum creatinine
<2.0mg dl-'
>2.0mg dl-'
IgG
IgA
IgD
IgM
Light chain only
Not secreting
K
L
Serum creatinine
Stage 1
<2.0mg dl-'
>2.0 mg dl-'
Stage II
<2.0mg dl-'
>2.0 mg dl-'
Stage III
<2.0mgdl-'
>2.0mg dl-'
298
43
220
77
7
1
31
5
206
135
78
76
2
93
90
3
170
132
38
100
49.3
50.7
87.4
12.6
64.5
22.6
2.1
0.3
9.1
1.4
60.4
39.6
22.9
27.2
49.9
was reached with 7.1 (4-10) courses in the PTC-VCR-P arm
and with 9.8 (range 6-15) courses in the MPH-P arm, which
correspond to 33.2 and 63.2 weeks of therapy (P<0.04).
Toxicity ofinduction therapy
Haematological toxicity could be evaluated in 166 patients
treated with MPH-P and in 59 patients on combination
chemotherapy.
Before starting treatment, a WBC count over 4.0 x I09 1'
was present in 88% of MPH-P-treated patients and in 84%
of PTC-VCR-P-treated patients. In the MPH-P group, a
reduction in WBC count below 2.0 x I091-' in one or more
courses occurred in 21.7% of patients and lasted 2-9 days.
In the combination therapy group, the corresponding figures
were 34.7% and 5-12 days (P = NS). No patient experienced
severe granulocytopenia (granulocytes less than 1.0 x 109
Most patients had a pretreatment platelet count over
100 x 1091-' and a reduction in platelet number below
60 x 109 1' occurred in 2.4% of patients treated with MPH-
P and in 8.1% of patients on combination chemotherapy.
Two patients treated with combination chemotherapy experi-
enced severe thrombocytopenia (platelets less than 30 x 109
The most frequent non-haematological side-effects of com-
bination chemotherapy were phlebothrombosis at the vein
site of the PTC injection (73.5% of patients) and alopecia
(9.3%). Other side-effects were more commonly observed
with combination chemotherapy than with MPH-P: nausea
and/or vomiting (11.8 vs 0.6%) and neurotoxicity (12.8 vs
2.4%).
Control ofthe disease
Progression from stage I to stage II or III disease was seen in
12 (29.3%) of the 40 patients who were left initially untreated
and in 4 (11.8%) of the 34 patients who received MPH-Pjust
after diagnosis (P = NS). The median time to progression
was 11 (3-25) months, without differences between the two
groups.
For all responsive patients, median duration of first res-
ponse was 23.1 months, a figure that was similar in patients
who received or did not receive maintenance therapy (Figure
1) and whose stage distribution was similar (Table III). Com-
pared with patients randomised to no maintenance (who
received a median of nine courses of MPH-P or of seven
courses of combination chemotherapy), patients randomised
to maintenance received a significantly (P<0.04) higher
amount of therapy, i.e. a median of 15 (6-28) courses of
MPH-P or of 11 (7-40) courses of combination chemo-
therapy (corresponding to median times on therapy of 23.2
and of 11 months).
Median duration of first response was not reached at 60
months in stage I, was 25.1 months in stage II and was 19.9
months in stage III, irrespective of receiving or not receiving
maintenance therapy (Table III). In stage III, response dura-
tion was somewhat, but not significantly, longer with MPH-P
than with PTC-VCR-P (17.4 vs 22.9 months).
Second induction therapy
A second induction therapy was administered to 183 patients,
but response was evaluable in 144 patients. Reasons for
non-evaluability were insufficient data for establishing res-
ponse (20 patients), loss to follow-up (18 patients) and major
protocol violation (eight patients).
The overall response rate was 28.5%, and there were no
differences between second response to MPH-P (34.0%) and
to combination therapy (25.3%). Response rate (Table IV)
tended to be higher in patients treated again with the first
induction regimen after relapse during no maintenance than
in patients treated with the alternative regimen because they
Table II Response to first induction treatment according with the stage of disease
Evaluable/entered R CR PR NR P ED
patients No. % No. % No. % No. % No. % No. % P
Stage I
No therapy 40/40 - - - - 12 29.3
MPH-P 34/38 11 32.3 3 8.8 8 23.5 19 55.9 4 11.8 - NS
Stage II
MPH-P 87/93 46 52.8 18 20.7 28 32.2 26 29.9 9 10.3 6 6.9
Stage III
MPH-P 85/87 30 35.3 20 23.5 10 11.8 25 29.4 15 17.6 15 17.6 NS PTC-VCR-P 75/83 36 48.0 18 24.0 18 24.0 20 26.7 5 6.7 14 18.6
All stages
MPH-P 206/218 87 42.2 41 19.9 46 22.3 70 34.0 28 13.6 21 10.2 NS
PTC-VCR-P 75/83 36 48.0 18 24.0 18 24.0 20 26.7 5 6.7 14 18.6
Overall 281/301 123 43.8 59 21.0 64 22.8 90 32.0 33 11.7 35 12.4
aEvaluable/entered patients = patients who were evaluable for response over those who received the indicated treatment. R,
response; CR, complete response; PR, partial response; NR, no response; P, progression; ED, early death (i.e. deaths before
response could be evaluated); MPH-P, melphalan and prednisone; PTC-VCR-P, combination chemotherapy with the association of
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Figure 1 Duration of first response in patients with multiple
myeloma who were randomised to receive or to not receive
maintenance therapy.
Table III Duration of first response in patients randomised to not
receive or to receive maintenance therapy
No
First treatment maintenance Maintenance P
All stages (no. of patients) 55 58
No therapy (no. of patients) 2 2
MPH-P (no. of patients) 37 38
PTC-VCR-P (no. of patients) 16 18
First response (months) 24.9 23.2 NS
Stage I (no. of patients) 6 7
No therapy (no. of patients) 2 2
MPH-P (no. patients) 4 5
First response (months) >60 >60 NS
Stage II
MPH-P (no. of patients) 19 21
First response (months) 24.8 30.3 NS
Stage III (no. of patients) 30 30
MPH-P (no. of patients) 14 12
PTC-VCR-P (no. of patients) 16 18
First response (months) 20.5 18.6 NS
MPH-P, melphalan and prednisone; PTC-VCR-P, combination
chemotherapy with Peptichemio, vincristine and prednisone.
were resistant or progressed or relapsed during maintenance.
There were no differences in second response rate between
MPH-P and combination chemotherapy.
The median duration of survival following second induction
therapy was 18.9 months; it was similar in 113 PTC-VCR-P-
treated patients (56 are alive) and in 70 MPH-P-treated
patients (20 are alive).
60 72
Survival duration
For all patients, median survival was 37.2 months. Median
survival was not reached at 78 months in stage I patients
(72% of patients are alive), was 46.3 months for stage II
patients and 24.3 months for stage III patients (Figure 2).
In stage I and III patients, median survival was not
influenced by the type of initial treatment, i.e. starting MPH-
P just after diagnosis or at progression in stage I (Figure 3)
and receiving MPH-P or PTC-VCR-P in stage III (Figure
4).
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Figure 2 Duration of survival in patients with different stages of
multiple myeloma.
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Figure 3 Duration of survival in stage I patients who were
randomised between receiving no therapy until progression or
melphalan (MPH) and prednisone (P) just after diagnosis.
Table IV Second response to induction treatment with MPH-P or with combination chemotherapy according with the outcome of
first induction therapy
Previous status of Evaluable/entered R CR PR NR P ED
patients patients No. % No. % No. % No. % No. % No. % P
Second response to MPH-P
On no maintenance
following MPH-P 16/21 6 37.5 3 18.7 3 18.7 0 0 3 18.7 7 43.7 NS
NR to PTC-VCR-P 16/20 5 31.2 1 6.2 4 25.0 4 25.0 2 12.5 5 31.2
P on PTC-VCR-P 3/5 1 33.3 0 0 1 33.3 0 0 1 33.3 1 33.3
Relapse during 18/24 6 33.3 1 5.5 5 27.7 6 33.3 3 16.6 3 16.6
PTC-VCR-P
All patients 53/70 18 34.0 5 9.4 13 24.5 10 18.9 9 17.0 16 30.2
Second response to PTC-VCR-P
On no maintenance
following PTC-VCR-P 9/11 4 44.4 1 11.1 3 33.3 1 11.1 1 11.1 3 33.3 NS
NR to MPH-P 43/51 11 25.6 3 14.3 8 18.6 19 44.2 3 14.3 10 23.2
P on MPH-P 20/24 7 35.0 4 20.0 3 15.0 1 5.0 4 20.0 8 40.0
Relapse during 19/27 4 21.0 1 5.3 3 15.9 3 15.9 3 15.9 9 47.4
MPH-P
All patients 91/113 23 25.3 9 9.9 17 18.7 24 26.4 11 12.1 30 32.9
aEvaluable/entered patients = patients who were evaluable for response over those who received the indicated treatment. R,
response; CR, complete response; PR, partial response; NR, no response; p, progression; ED, early death (i.e. death before
response could be evaluated); MPH-P, melphalan and prednisone; PTC-VCR-P, combination chemotherapy with Peptichemio,
Vincristine and prednisone.
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Figure 4 Duration of survival in stage III patients who were
randomised between receiving melphalan (MPH) and prednisone
(P) or combination chemotherapy with Peptichemio (PTC), vin-
cristine (VCR) and P as first induction treatment.
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Figure S Duration of survival in responsive patients who were
randomised to receive or to not receive maintenance therapy.
Table V Causes of death
Patients who died 202
Patients whose cause of death is known
Causes related to MM (%)
Infections
Renal insufficiency
Hypercalcaemia
Hyperviscosity
Causes poorly or not related to MM (%)
Stroke
Myocardial infarction
Cardiac failure
Solid tumours
Acute leukaemia
Peritonitis
Following ABMT
141
106 (75.2)
46
33
23
4
35 (24.8)
14
7
2
8
2
1
1
For all responsive patients, median survival was indepen-
dent of receiving or not receiving maintenance (Figure 5).
Causes ofdeath
These are known for 141 of 202 deaths and are detailed in
Table V. Acute leukaemia occurred in a responsive 64-year-
old stage IIIA patient who received 12 courses of MPH-P
and no further maintenance and in a 72-year-old stage IIA
responsive patient who received 18 courses of MPH for both
induction and maintenance. Eight solid tumours occurred in
six MPH-P-treated patients (two non-responders had lung
and one had laryngeal cancer, one responsive patient on no
maintenance had a gastric cancer and another on main-
tenance had prostate cancer, and one patient not evaluable
for response had a bladder cancer) and in two PTC-VCR-P-
treated patients (one with colon and the other with bladder
cancer).
Discussion
The quite long overall survival of this large population of
patients with MM was unrelated to the aggressiveness of
induction policy and to the amount of chemotherapy given
after the maximal tumour reduction had been reached. This
reflects the fact that within each stage of the disease the same
survival occurred independently of the less or more aggres-
sive induction treatment and of discontinuing or continuing
maintenance after response.
So, patients with early (stage I) disease fared equally when
left untreated until disease progression or when treated with
MPH-P just after diagnosis, at least during the first 51
months of follow-up. Similar data have been reported
recently (Hjorth et al., 1993). Differences could appear with a
longer follow-up of a larger group of patients, and we are
continuing to follow-up of patients of this series and also
recruiting further patients into a protocol started subse-
quently (MM90). Non-randomised studies (Harley et al.,
1979; Cavagnaro et al., 1980; Salmon et al., 1983; Cooper et
al., 1986; Riccardi et al., 1986; Kildahl-Andersen et al., 1988;
MacLennan et al., 1988; Hjorth et al., 1990; Boccadoro et al.,
1991) and their meta-analysis (Gregory et al., 1992) make it
unlikely that chemotherapies more aggressive than MPH-P
are of benefit in early MM, with the possible notable excep-
tion of high-dose chemotherapy followed by bone marrow
transplantation in young patients (Garthon et al., 1991).
Patients with advanced (stage III) disease did not survive
longer if treated with PTC-VCR-P rather than with MPH-P,
and this does not confirm the suggestion that combination
chemotherapy (with different drug associations) is better than
MPH-P in advanced MM. This suggestion has come from
the retrospective analysis of some studies (Harley et al., 1979;
Salmon et al., 1983; Cooper et al., 1986; MacLennan et al.,
1992) and from a recent meta-analysis (Gregory et al., 1992).
None, however, of these studies was originally devised to
compare MPH-P with more aggressive regimens in advanced
disease.
Finally, there is no apparent reason to continue cytostatic
maintenance therapy once maximum tumour response has
been achieved, as first suggested in an MRC Trial (McLen-
nan et al., 1985), although there was not an increased
incidence of acute leukaemia due to maintenance (but the
follow-up may have been inadequate).
An indication from this study, as from the Vth MRC trial
(MacLennan et al., 1992), is that achieving the maximal
tumour reduction by administering additional chemotherapy
after response allows a good survival, possibly through a
long first response duration. With this approach, the median
duration of response is long and not improved by main-
tenance. In other randomised series in which the induction
treatment was stopped after a fixed number of courses (Peest
et al., 1988) or after a fixed period of therapy (Cohen et al.,
1979; Kildahl-Andersen et al., 1988), the duration of shorter
responses was improved by maintenance, but there was not a
survival advantage over stopping the treatment after induc-
tion. Cytostatic maintenance may indeed continue the effect
of previous induction therapy in selecting plasma cell clones
with aneuploidy (Montecucco et al., 1984) and/or expressing
the p170 glycoprotein (Ucci et al., 1992), which are often
drug resistant. Clinically, this is shown by the fact that in this
as in other studies (Alexanian et al., 1978; Cohen et al., 1986)
the second response rate was lower in patients who pro-
gressed or relapsed during maintenance than in those who
relapsed during no maintenance.
The intrinsic activity and the limited cross-resistance of the
treatment regimens used, i.e. the MPH-P and PTC-VCR-P
schedule, is another reason for the good survival in this
multicentre study, which required a quite high (20%) mini-
mum percentage of bone marrow plasma cells for diagnosis
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and included a large proportion of patients with advanced
MM.
The effectiveness of MPH-P in treating MM is well known.
The association of PTC-VCR-P is confirmed (Cavo et al.,
1981; Merlini et al., 1982, 1985; Riccardi et al., 1986; Buzaid
& Durie, 1988) as being at least as effective as MPH-P in
inducing response, although it has the disadvantage of
parenteral administration and of more pronounced haemato-
logical and, especially, non-haematological side-effects. In
particular, the sequential use of MPH-P and PTC-VCR-P
seems to be a valuable policy with relatively little cross-
resistance for the overall treatment of MM, in that it allows
a high second response rate in patients failing on the alterna-
tive regimen. First responses to PTC-VCR-P, as to other
combination chemotherapies including VAD (Abramson et
al., 1982; Monconduit et al., 1992), are confirmed to be
shorter lived (Riccardi et al., 1986) than those induced with
MPH-P, probably because of residual plasma cell recruitment
following the rapid reduction in tumour mass (Riccardi et al.,
1978, 1984, 1985). However, obtaining a rapid response with
combination chemotherapy could be of value in heavily com-
promised patients, such as those with advanced MM with
renal insufficiency, and could outweigh the disadvantage of
tumour cell recruitment.
In this investigation, it is difficult to evaluate the additional
clinical importance of the fact that Protocol MM87 provided
indications for an orderly approach to third- and fourth-line
treatment and for supportive therapy (including the use of
high-dose androgens for stimulating haemopoiesis and of
bisphosphonates for hypercalcaemia and for counteracting
bone destruction, and the close survey and treatment of both
renal insufficiency and infections). Also, every 6 months the
correct application of the protocol was checked, and prob-
lems were discussed at cooperative group meetings. Participa-
tion in a cooperative protocol has ameliorated the clinical
results in acute non-lymphoblastic leukaemia (Boros et al.,
1985; Riccardi et al., 1987).
In conclusion, the results of this study are against increas-
ing cytostatic treatment in patients with MM, provided that
the drugs used for induction are intrinsically effective on
neoplastic plasma cells and useful in achieving tumour reduc-
tion (which may be much less than 50%, and minimal in a
number of patients) (A. Riccardi, unpublished observations).
MPH-P and PTC-VCR-P are equally effective, but PTC-
VCR-P causes more haemotological and, especially, non-
haematological toxicity. Thus, the overwhelming majority of
patients, independent of stage, can be managed with MPH-P
as initial treatment. In patients with early disease, cytostatics
may be delayed at the time of disease progression, while
heavily compromised patients who require rapid response
could benefit from the association of PTC-VCR-P. The
sequential use of MPH-P and of PTC-VCR-P is an effective
overall regimen for MM, because it allows a high second
response rate in patients failing on the alternative
regimen.
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